Nonalcoholic Steatohepatitis – Epidemiology – Emerging Markets
Clarivate Epidemiology’s coverage of non-alcoholic steatohepatitis (NASH) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of NASH for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy is also forecast across the major mature pharmaceutical markets.
Clarivate Epidemiology’s NASH forecast will answer the following questions:
- Of all people with NASH, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
- Of all people diagnosed with NASH, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of NASH over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 16 NASH patient populations, as follows:
- Total prevalent cases
- Obese prevalent cases
- Total prevalent cases with fibrosis stage f0-f1
- Total prevalent cases with fibrosis stage f2-f4
- Diagnosed prevalent cases
- Diagnosed prevalent cases with fibrosis stage f0
- Diagnosed prevalent cases with fibrosis stage f1
- Diagnosed prevalent cases with fibrosis stage f2
- Diagnosed prevalent cases with fibrosis stage f3
- Diagnosed prevalent cases with fibrosis stage f4
- Drug-treated prevalent cases
- Non-drug-treated prevalent cases
- … and many more (details available on request).
Note: Coverage may vary by country.
Table of contents
- Nonalcoholic Steatohepatitis - Epidemiology - Emerging Markets
- Introduction
- Key Findings
- Total Prevalence of NASH per 1,000 Among People of All Ages in 2021 and 2031
- Total Prevalence of NASH per 1,000 Among People of All Ages in 2021 and 2031
- Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of NASH Over the Next Ten Years
- Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of NASH Over the Next Ten Years
- Epidemiology Data
- Methods
- Reference Materials
- Introduction
Shilpa Thakur, M.P.H., is an epidemiologist at Clarivate. Previously, she monitored HIV sentinel surveillance in Himachal Pradesh. She has also studied the patterns of antimicrobial resistance in India. She received her M.P.H. from the Postgraduate Institute of Medical Education and Research with a specialization in epidemiology and biostatistics.
Swarali Tadwalkar, M.P.H., is a principal epidemiologist at Clarivate. Previously, she was involved in primary and secondary healthcare research, including projects in digital health, health policy and management, and health economics and outcomes research (HEOR). Ms. Tadwalkar also coordinated various nongovernmental public health projects focusing on access to treatment for hepatitis and human papilloma virus. She received her M.P.H. from the University of South Florida in Tampa.